Invizius Limited news
- £1 million grant will support first-in-human clinical trials of H-Guard
Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of ha
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology.
Globally there are 3.5 million patients who are solely dependent on renal replacement therapy
- £5.3 million financing to complete First-in-Man safety study
- Led by Mercia, Downing Ventures, Old College Capital, Scottish Enterprise and Solvay Ventures; welcomes new investors Calculus Capital and Dr Jonathan Milner
Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of £5.3 million. The financing was led by existing investors Mercia, Downing
Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank. Invizius is conducting pre-clinical testing and manufacturing, as it prepares to enter clinica
Invizius, the University of Edinburgh spin-out which is developing potentially lifesaving products for dialysis patients, has made four high-profile appointments as it prepares to enter the next stage of its development.
The new directors all have international experience in leading pharma and life sciences businesses. Their arrival follows the recent £2.75m investment in Invizius by a consortium of investors including Mercia, Downing Ventures, the University of Edinburgh
Invizius, the University of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75m from a consortium of investors.
The funding round was led by Mercia and included Downing Ventures, the University’s Old College Capital fund and the Scottish Investment Bank. The latest investment will support the company as it conducts pre-clinical testing and manufacturing, and prepares to enter clinical trials and to
Invizius, a University of Edinburgh spinout whose technology promises to improve the lives of millions of dialysis patients, has been named Best Innovative MedTech company at the prestigious OBN Awards.
The company’s success in the awards, which have a high profile in the life sciences sector, follows on from a seed investment of £500,000 from Mercia Fund Managers in May 2018.
Invizius’ H-Guard™ p
A spinout company whose technology could save the lives of thousands of dialysis patients has secured £500,000 from Mercia Asset Management, in the first investment deal since Mercia’s partnership with the University of Edinburgh was announced in November 2017.
Invizius stems from years of research by Invizius co-founder, Dr Andy Herbert and his team, who believe they have found a way to reduce the risk of cardi